登录

First Wave Biopharma将通过直接发行筹集约400万美元的收益

First Wave Biopharma to raise about $4M of proceeds in direct offering

seekingalpha 2024-03-04 21:28 翻译由动脉网AI生成,点击反馈

可切换为仅中文


First Wave BioPharma (NASDAQ:FWBI) entered into a securities purchase agreement with a certain institutional investor for the purchase and sale of 525,625 shares at $7.61 per share in a registered direct offering. In addition, in a concurrent private placement, the company will issue to the investors warrants to purchase up to 525,625 shares of common stock.

First Wave BioPharma(纳斯达克股票代码:FWBI)与某机构投资者签订了一份证券购买协议,以注册直接发售的形式,以每股7.61美元的价格购买和出售525625股。此外,在同时进行的私募中,该公司将向投资者发行权证,以购买多达525625股普通股。

The warrants have an exercise price of $7.48 per share. The gross proceeds to the company from this offering are expected to be approximately $4M. Source: Press Release More on First Wave BioPharma First Wave expecting 'significant' investments if ImmunogenX deal closes First Wave Biopharma announces exercise of warrants, issuance of new warrants in private placement for $4.8M gross proceeds priced Seeking Alpha’s Quant Rating on First Wave BioPharma Historical earnings data for First Wave BioPharma Financial information for First Wave BioPharma .

认股权证的行权价格为每股7.48美元。此次发行给该公司的总收益预计约为400万美元。来源:有关第一波生物制药的更多新闻稿如果ImmunogenX交易结束,第一波生物制药预计将进行“重大”投资第一波生物制药宣布行使认股权证,以480万美元的总收益发行私募新权证,以寻求Alpha对第一波生物制药历史收益数据的量化评级,为第一波生物制药提供财务信息。

推荐阅读

招 94人,无锡市锡山区医疗卫生单位 2024年公开招聘

丁香医学生 2024-07-13 17:30

迈向个人健康数据国家研究数据基础设施的互操作性格局

Nature 2024-07-13 17:08

重庆在全国率先探索公共卫生医师处方权试点 5个区县打头阵

seekingalpha

412篇

最近内容 查看更多

2024年迄今为止表现最好的10只生物技术股

2024-03-07

Creative Medical股价上涨18%,脆性1型糖尿病候选疗法获授予孤儿药称号

2024-03-06

Cyclacel Pharmaceuticals获得290万美元的研发税收抵免

2024-03-06

产业链接查看更多